Full Press Release Details
Granted Key European Patent for its Stem Cell Selection Technology
TEL AVIV, Israel, August 7, 2018 -- Cellect
Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today the European Patent
Office has granted the company a patent for its ApoTainer device which is used in conjunction with its platform ApoGraft
technology titled, "Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof".
The patent addresses Cellect's devices and methods for
specifically selecting desired stem cells from a heterogeneous cell population for use in a range of medical indications. Through
negative selection, Cellect's technology identifies mature cells that can be harmful to the recipient and selectively eliminates
those cells through apoptosis (cell death). Cellect's patented technology is designed to produce safe and ample quantities
of stem cells ready for dosing in patients in a wide range of disease states from oncology to auto-immune diseases. The latest
patent granted to the Company covers claims including Cellect's method for preventing graft vs. host disease (GvHD) while
retaining potent anti-cancer graft vs. tumor (GvT) activity using the ApoTainer device.
"This patent in Europe further expands our robust intellectual
property estate which includes seven families of global patent applications with several issued in the U.S. and EU for the concept
of using apoptosis for stem cell selection, methods of use, and composition of matter for the ApoTainer . We expect to have
protection against other devices looking to use apoptosis-inducing ligands, as indicated in the patent, for the process of cell
selection," stated Cellect CEO Dr. Shai Yarkoni. "We believe the value of this patent is underscored by the favorable
initial results reported in our open label Phase I/II trial in GvHD which is actively recruiting and treating patients."
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a breakthrough
technology for the selection of stem cells from any given tissue that aims to improve a variety of stem cell-based therapies.
The Company's technology is expected to provide research, hospitals
and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and
procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow
transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking
statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the
use of forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will",
"project", "forecast", "continue" or "anticipate" or their negatives or variations
of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release when we discuss the Company's expectations regarding
the protection that the patent may provide. These forward-looking statements and their implications are based on the current
expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions
from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical
results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors,
among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's
history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable
terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet
working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable
pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted
by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source
adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic
partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual
property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive
companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's
technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development
of its products.. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company
undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future
developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks
and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual
Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission ("SEC"),
which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer